Global Improvement and Patient Satisfaction: Results from a Long-Term, Open-Label, Rollover Study of Valbenazine in Tardive Dyskinesia

被引：0
|
作者：
Lessig, S.
Marder, S.
Verghese, C.
Burke, J.
Jimenez, R.
Siegert, S.
Liang, G.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
92
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [41] Efficacy of Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia: Results of a Long-Term Extension Study (KINECT 3 Extension)
    Grigoriadis, Dimitri
    Comella, Cynthia
    Remington, Gary
    Jimenez, Roland
    Burke, Joshua
    Christopher, O'Brien
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S213 - S214
  • [42] IMPROVEMENTS OVER TIME WITH LONG-TERM VALBENAZINE IN OLDER AND ELDERLY PATIENTS WITH TARDIVE DYSKINESIA
    Sajatovic, Martha
    Alexopoulos, George
    Roque, Autumn
    Jen, Eric
    Lundt, Leslie
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2023, 31 (03): : S126 - S127
  • [43] Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials
    Comella, Cynthia
    Singer, Carlos
    Kane, John
    Farahmand, Khodayar
    Burke, Joshua
    Siegert, Scott
    NEUROLOGY, 2019, 92 (15)
  • [44] Patient Preference, Satisfaction, and Improved Clinical Global Impression of Change with Rimegepant 75 mg for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study
    Turner, I.
    Pavlovic, J. M.
    Lipton, R. B.
    Croop, R.
    Stock, E. G.
    Thiry, A.
    Conway, C. M.
    Lovegren, M.
    Coric, V.
    L'Italien, G.
    Jensen, C. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 102 - 102
  • [45] Global Improvements and Psychiatric Stability in Adults with Tardive Dyskinesia: Post Hoc Analyses of Two Long-Term Valbenazine Studies
    Cutler, Andrew
    Jain, Rakesh
    Bloom, Alon
    Siegert, Scott
    Lundt, Leslie
    NEUROLOGY, 2023, 100 (17)
  • [46] Effect of brexpiprazole on long-term remission in adults with schizophrenia: results of an open-label, long-term study
    Baker, R.
    Jin, N.
    Weiller, E.
    Weiss, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S952 - S952
  • [47] Real-World Evaluation of Patient Characteristics and Disease Management in Long-Term Valbenazine Treatment in Adults with Tardive Dyskinesia
    Goldberg, E.
    Yonan, C.
    Longo, N.
    Cratty, H.
    Nicosia, M.
    Sampalis, J.
    Carmack, T.
    Siegert, S.
    Angelov, A.
    MOVEMENT DISORDERS, 2020, 35 : S39 - S39
  • [48] LONG-TERM TREATMENT WITH VALBENAZINE 40 MG ONCE-DAILY IN ADULTS WITH TARDIVE DYSKINESIA
    Chepke, C.
    Marder, S. R.
    Comella, C. L.
    Singer, C.
    Farahmand, K.
    Shah, C.
    Lundt, L.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E119 - E120
  • [49] Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from Three Studies
    Remington, Gary
    Factor, Stewart
    Comella, Cynthia
    Liang, Grace
    Burke, Joshua
    O'Brien, Christopher
    NEUROLOGY, 2017, 88
  • [50] Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data From Three Studies
    Remington, Gary
    Comella, Cynthia
    Grigoriadis, Dimitri
    Liang, Grace
    Burke, Joshua
    O'Brien, Christopher
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S212 - S213
12345